To determine whether the chemoresistance was associated with Skp2-mediated MLKL downregulation in NSCLC cells, we examined the efficacy of the Skp2 inhibitor, SZL P1-41, in abrogating cisplatin resistance. The gene discussed is SKP2; the disease is non-small cell lung carcinoma.